Correlations and mechanistic data from earlier trials suggest that these inflammatory pathways may trigger the release of IP-10, Galectin-3, Osteopontin and Pentraxin-3, causing left ventricular remodelling in CAD and NSTEMI patients. This evidence concerns the gene CXCL10 and coronary artery disorder.